Follow The Filings

CORZ Core Scientific Inc.

Financials, filed as CORE SCIENTIFIC INC NEW (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Bought by 3 managers in 2026 Q2, sold by 3

  • 6 Owners
  • #252
  • Max 3.3%
  • Master 0.06%
  • $1.1B
  • 2 new 1 add 2 reduce 1 exit

In 2026 Q2, 2 managers opened positions, 1 added, 2 trimmed, and 1 sold out.

Who owns this now

Largest portfolio weights among holders, up to 3.3% (Situational Awareness). Not free-float ownership.

  1. Situational Awareness 3.3%
  2. Howard Marks Reduce 1.8%
  3. Ben Hoskin Add 0.59%
  4. Chase Coleman New 0.09%
  5. Dan Loeb New 0.03%
  6. George Soros Reduce 0.01%

Who owns CORZ

Sorted by value, long equity only, as of 2026 Q2.

History
Situational Awareness 3.3% Hold 26,008,473 $666M History
Ben Hoskin, Value Aligned Research Advisors 0.59%, was 0.56% Add +19.0% 9,187,797 $235M History
Howard Marks, Oaktree Capital Management 1.8%, was 2.1% Reduce −46.6% 4,993,708 $128M History
Chase Coleman, Tiger Global Management 0.09% New 0.09% 817,000 $21M History
Dan Loeb, Third Point 0.03% New 0.03% 54,000 $1.4M History
George Soros, Soros Fund Management 0.01%, was 0.05% Reduce −89.3% 35,147 $899K History
Ning Jin, Avantyr Capital Partners exited 2026 Q2 Last 2026 Q1 0.57% Exit −0.57% 798,137 $12M History

6 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by CORZ's executives, directors and 10% owners in the last 12 months, from their Form 4s

All CORZ insider trades
  • $552K bought by 2 insiders
  • None no sales outside a trading plan
  • $6.2M sold by 1 insider under 10b5-1 plans
  1. Todd M Duchene See remarks
    Planned sale
    $139K 10,000 shares at $13.87 0.9% of stake
    Traded Oct 19 Filed Oct 20
    ↗
  2. Todd M Duchene See remarks
    Planned sale
    $151K 10,000 shares at $15.12 0.9% of stake
    Traded Oct 12 Filed Oct 14
    ↗
  3. Todd M Duchene See remarks
    Planned sale
    $163K 10,000 shares at $16.31 0.8% of stake
    Traded Oct 5 Filed Oct 7
    ↗
  4. Todd M Duchene See remarks
    Planned sale
    $168K 10,000 shares at $16.76 0.8% of stake
    Traded Sep 28 Filed Sep 30
    ↗
  5. Todd M Duchene See remarks
    Planned sale
    $184K 10,000 shares at $18.37 0.8% of stake
    Traded Sep 21 Filed Sep 23
    ↗
  6. Eric Stanton Weiss Director
    Buy
    $98K 6,000 shares at $16.33 +2.3% to stake
    Traded Sep 15 Filed Sep 17
    ↗
  7. Todd M Duchene See remarks
    Planned sale
    $171K 10,000 shares at $17.14 0.8% of stake
    Traded Sep 14 Filed Sep 16
    ↗
  8. Todd M Duchene See remarks
    Planned sale
    $187K 10,000 shares at $18.67 0.8% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  9. Todd M Duchene See remarks
    Planned sale
    $162K 10,000 shares at $16.23 0.5% of stake
    Traded Aug 31 Filed Sep 2
    ↗
  10. Todd M Duchene See remarks
    Planned sale
    $174K 10,000 shares at $17.45 0.5% of stake
    Traded Aug 24 Filed Aug 26
    ↗
  11. Elizabeth Crain Director
    Buy
    $110K 6,000 shares at $18.33 +9.2% to stake
    Traded Aug 20 Filed Aug 24
    ↗
  12. Eric Stanton Weiss Director
    Buy
    $134K 7,000 shares at $19.19 +2.8% to stake
    Traded Aug 18 Filed Aug 20
    ↗
  13. Todd M Duchene See remarks
    Planned sale
    $201K 10,000 shares at $20.10 0.5% of stake
    Traded Aug 17 Filed Aug 19
    ↗
  14. Todd M Duchene See remarks
    Planned sale
    $200K 10,000 shares at $19.97 0.5% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  15. Todd M Duchene See remarks
    Planned sale
    $222K 10,000 shares at $22.23 0.5% of stake
    Traded Aug 3 Filed Aug 5
    ↗

Also filed in the last 12 months, not counted as buying or selling: 19 share withholdings for taxes, 13 stock grants, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
8-K 7.01 Filing Doc
8-K 1.01,2.03,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
8-K 3.02,7.01,9.01 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 2 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $502.4M $510.67M $319.02M
Gross profit $123.46M $121.07M $37.9M
Gross margin * 24.6% 23.7% 11.9%
Net income -$0.246B -$1.44B -$0.289B
Net margin * -49.1% -281.6% -90.5%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $97.02M $903.96M $895.54M
Total non-current assets * $0.615B -$0.24B $1.45B
Total assets $0.712B $0.664B $2.35B
Total current liabilities $488.42M $134.56M $781.4M
Total non-current liabilities * $0.821B $2.28B $2.53B
Total equity -$0.597B -$1.18B -$0.963B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $65.11M $42.9M $278.25M
Cash from investing -$3M -$95.19M -$740.75M
Cash from financing -$44.65M $819.57M -$63.1M
Net change in cash $17.47M $767.27M -$525.6M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.